SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulcrum Therapeutics, Inc. – FULC

NEW YORK, March 3, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980….

Leave a Reply

Your email address will not be published. Required fields are marked *